What is HIND's market cap?

$12.25M, based on the Nov 4 close of $1.75.

Does Vyome Holdings pay a dividend?

No regular cash dividend has been paid in the last year.

How much of HIND is sold short?

20.7K shares, 1.2% of float, as of Oct 15, 2026.

What sector is HIND in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · HINDHealthcarePharmaceuticals

Vyome Holdings, Inc. Common Stock (HIND)

$1.75−1.41%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$1.75▼ 72.35% in range

Nov 3, 2025Low $1.70 · High $6.31Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Vyome Holdings closed at $1.75 on Nov 4, down 1.41%, within 2.6% of its 52-week closing low. Volume of 5.8K shares was 0.56× its 20-day average (below normal).

Split-adjusted performance: -15.3% over one month, -20.7% over six months, -72.3% over one year.

In the quarter ended Jun 30, 2026, revenue was $26.95K, with a net margin of -2543.3%.

Short interest was 20.7K shares at the Oct 15 settlement, down 21.2% from the prior report (1.2% of float, 1.9 days to cover).

Market cap$12.2M7.0M shares

Revenue · quarter$27.0K—

Diluted EPS$-0.10—

P/E · TTM—P/S 94.4×

Net margin-2,543.3%Gross 43.2%

Dividend yieldNone

52-week range1.70 – 6.31−72.3% from high

Volume5.8K0.56× 20-day avg

Volatility · 60d41.1%Annualised

Short % of float1.2%1.9 days to cover

Net cash$7.9MCash $7.9M

Next earnings—Not scheduled

Split-adjusted performance

1W +1.5%1M −15.3%3M −18.5%6M −20.7%YTD −49.3%1Y −72.3%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum57

Revenue growth—

Net margin11

Value (low P/E)—

Size18

Industry medians: 6-month return −25.3%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short20.7K−21.2% vs prior

Days to cover1.9Settled Oct 15

% of float1.2%

Short vol. 10d22.2%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
HINDVyome Holdings	$1.75	−1.41%	−20.7%	—	−2543.3%	—	$12.2M
CLRBCellectar Biosciences INC NEW	$1.30	−1.15%	−63.3%	—	—	—	$12.2M	Compare
LPCNLipocine	$1.46	−0.34%	−40.1%	−100.0%	—	—	$12.0M	Compare
TVRDTvardi Therapeutics	$0.8848	+5.98%	−75.8%	—	—	—	$11.8M	Compare
AEONAEON Biopharma	$0.2165	+2.03%	−76.1%	—	—	—	$12.8M	Compare
LSTALisata Therapeutics	$1.09	−0.46%	−66.7%	−100.0%	—	—	$11.7M	Compare
BFRIBiofrontera	$0.8900	+0.01%	−21.9%	+32.9%	−5.0%	—	$13.2M	Compare
DAREDare Bioscience	$0.6745	+3.78%	−78.7%	—	−1590.4%	—	$13.3M	Compare
BIVIBioVie	$1.30	−25.14%	−22.0%	—	—	—	$11.2M	Compare

News about Vyome Holdings

All news →

No recent articles focused on Vyome Holdings.

Quick answers

What does Vyome Holdings do?: Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne.
What is HIND's market cap?: $12.25M, based on the Nov 4 close of $1.75.
Does Vyome Holdings pay a dividend?: No regular cash dividend has been paid in the last year.
How much of HIND is sold short?: 20.7K shares, 1.2% of float, as of Oct 15, 2026.
What sector is HIND in?: Healthcare, in the Pharmaceuticals industry.

About Vyome Holdings

Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.

HQ: San Clemente, CA18 employeesListed Aug 15, 2025vyometx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology